{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-017639","form_type":"8-K","ticker":"TVGN","cik":"0001860871","company_name":"Tevogen Bio Holdings Inc.","filed_at":"2023-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.229101+00:00","generated_at":"2026-06-19T21:00:12.359878+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Semper Paratus extends BC deadline to Dec 2023; $332M redeemed, trust reduced to $25M","bullets":["Shareholders approved charter amendment extending business combination deadline from Feb 8, 2023 to Dec 15, 2023.","Holders of 32,116,947 public shares elected redemption, receiving ~$332M ($10.34/share) from trust.","Post-redemption, trust account balance is ~$25M with only 2,383,053 public shares outstanding.","Class B shareholders converted all 11,983,333 Class B shares to Class A shares on a 1-for-1 basis."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-017639","json":"https://secwatch.observer/filing/0001104659-23-017639.json","markdown":"https://secwatch.observer/filing/0001104659-23-017639.md","text":"https://secwatch.observer/filing/0001104659-23-017639.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860871/000110465923017639/0001104659-23-017639-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860871/000110465923017639/tm236129d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T21:00:12.359878+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"757b67044ec830e875bc6a7e42280a802e116e44","claim":"Tevogen Bio Holdings Inc.: Approved an amendment to extend the deadline for consummating an initial business combination from February 8, 2023 to December 15, 2023 (effective 2023-02-03).","evidence_excerpt":"the shareholders of the Company approved an amendment (the “Charter Amendment”) to the Company’s Amended and Restated Memorandum and Articles of Association to extend the date by which the Company must consummate an initial business combination from February 8, 2023 to December 15, 2023. Under Cayman Islands law, the Charter Amendment took effect upon approval by the shareholders.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860871/000110465923017639/0001104659-23-017639-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-02-03"}],"fact_type":"governance_change"},{"claim_id":"1568e202bda27b6531385b1cecdbbe2eef196011","claim":"Tevogen Bio Holdings Inc. shareholders approved Approval of Charter Amendment at the 2023-02-03 meeting.","evidence_excerpt":"otes: For Against Abstain 35,386,187 4,266,453 0 The adjournment proposal was not presented to the shareholders because there were sufficient votes to approve the Charter Amendment.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860871/000110465923017639/0001104659-23-017639-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-02-03"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}